Importance of the GH/IGF-1 Axis for Human Substrate and Energy Metabolism During Calorie Restriction
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01209429 |
Recruitment Status
:
Completed
First Posted
: September 27, 2010
Last Update Posted
: September 13, 2011
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Healthy | Drug: GH hormone infusion Behavioral: 42 hour fast Behavioral: 12 hour fast | Not Applicable |
It has been shown that calorie restriction enhances the length of life in yeast, worms, fish and rodent. Whether this elongation of life due to calorie restriction can be applied to humans is not known. However, it is a fact that calorie restriction will decrease the risk of developing metabolic disturbances such as diabetes, hypertension and atherosclerosis.
On the molecular level the specific relations are not fully understood. This study will investigate the possible connection between SITR1 and the relation to the GH/IGF-I axis and STAT5b in healthy men. The participant will fast 42 and 12 hours respectively, and have GH or placebo infusions. The design is a classical 2x2 design and will be randomized.
Knowledge of the interactions between calorie restriction, SIRT1, STAT5b and the GH/IGF-I axis will apply important information about the relations between aging, energy metabolism and metabolic disturbances.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 10 participants |
Allocation: | Randomized |
Intervention Model: | Factorial Assignment |
Masking: | Single (Participant) |
Primary Purpose: | Basic Science |
Official Title: | Importance of the GH/IGF-1 Axis for Human Substrate and Energy Metabolism During Calorie Restriction |
Study Start Date : | September 2010 |
Actual Primary Completion Date : | September 2011 |
Actual Study Completion Date : | September 2011 |
Arm | Intervention/treatment |
---|---|
Experimental: 42 hour fast/GH infusion |
Drug: GH hormone infusion
Norditropin 30 ng/kg/min
Other Names:
Behavioral: 42 hour fast
The participant will be fasting 42 hours prior to the start of the study day, drinking water is allowed
Other Name: No other name
|
Experimental: 42 hour fast/Placebo infusion |
Behavioral: 42 hour fast
The participant will be fasting 42 hours prior to the start of the study day, drinking water is allowed
Other Name: No other name
|
Experimental: 12 hour fast/GH infusion |
Drug: GH hormone infusion
Norditropin 30 ng/kg/min
Other Names:
Behavioral: 12 hour fast
12 hour fast will be used as a control scenario to 42 hour fast
Other Name: No other name
|
Placebo Comparator: 12 hour fast/Placebo infusion |
Behavioral: 12 hour fast
12 hour fast will be used as a control scenario to 42 hour fast
Other Name: No other name
|
- Description of intracellular pathways to clarify the interplay between calorie restriction, SIRT1, STATb5, and the GH/IGF-I axis [ Time Frame: 6 hour study days ]All study days consists of 3 hour basic periods and 3 hours hyperinsulinemic, euglycemic clamp.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 70 Years (Adult, Senior) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- healthy lean men
- age >18
Exclusion Criteria:
- metabolic disturbances
- alcohol drug abuse
- malign disease: current or previous

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01209429
Denmark | |
University Hospital of Aarhus, Norrebrogade | |
Aarhus, Denmark, 8000 |
Principal Investigator: | Jens Otto L Jørgensen, Professor | University Hospital of Aarhus |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Birgitte Nellemann, MD PhD student, University of Aarhus |
ClinicalTrials.gov Identifier: | NCT01209429 History of Changes |
Other Study ID Numbers: |
M-20100150 |
First Posted: | September 27, 2010 Key Record Dates |
Last Update Posted: | September 13, 2011 |
Last Verified: | September 2011 |
Keywords provided by Birgitte Nellemann, University of Aarhus:
Calorie restriction GH/IGF-I axis STATb5 SIRT1 |
Intracellular signaling peptides and proteins Fasting Growth hormone IGF-1 |
Additional relevant MeSH terms:
Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs |